The Taoiseach acknowledges there have been “communication issues” in the process used to reimburse rare disease medicines. Across the past four years, officials have approved reimbursement for a large number of treatments: 70 rare disease drugs have been approved since 2021. The reporting focuses on the government’s handling of communications around how the rare drugs reimbursement system works and how information about approvals and processes is provided to stakeholders. Both outlets describe the same core point: while the reimbursement approvals continue to progress, the Taoiseach accepts that communication around the process has not always been as clear as it should be. The coverage does not dispute the overall scale of approvals, but it highlights that the government is attentive to the way details and updates are communicated. The articles present the acknowledgment as an effort to address concerns about transparency and messaging related to rare disease drug reimbursement.